

INVITATION

EAACI CONGRESS

BILASTINE

Setting safety as a benchmark







Vienna Austria Bila0615.9000.0316

Satellite Symposium, Vienna 2016 June 12nd 2016 at 5:30 p.m. Room Lehar 1





Setting safety as a benchmark

INVITATION

Dear Participant

On behalf of FAES FARMA and the MENARINI Group, it is a great pleasure to invite you to be present at the 9th Bilastine EAACI Symposium to be held at 17:30h on Sunday 12th June 2016 at the EAACI 2016 Congress in Vienna, Austria.

FAFS FARMA and the MENARINI group have shown their commitment to the field of allergic diseases by developing and launching Bilastine, the newest and most modern non-sedating H1-antihistamine. The aim of the 2016 EAACI Symposium is to increase and refine knowledge regarding the development of the newest H1-antihistamines for use in the paediatric population and its overall safety.

We look forward to your participation in this informative and stimulating session.

PROGRAMME

Chairmen:

Prof. Antonella Muraro, Italy Prof. Hans Ulrich Wahn, Germany

17:30

" Ontogeny and the science of dosing in children " Prof. Martin Church, Germany

17:45

" Model-based drug development: why focus on paediatrics?" Dr. Mónica Rodriguez, Spain

18:00

"Paediatric allergic rhinitis and urticaria: the role of bilastine" Prof. Nikos Papadopoulos, Greece

18:30

"Bilastine: the safety car" Prof. Ralph Mösges, Germany

Property:













